Ma Tiger Synthetic-Up Neutral ETF H (276000)

Overview

Linc AB is a distinguished player in the field of private equity and venture capital, with a specialized focus on the pharmaceutical, life-science, and med-tech sectors. Founded in 1991 and headquartered in Stockholm, Sweden, the firm has carved a niche in supporting companies at various stages of their lifecycle. Their investment strategy uniquely positions them to engage with early-stage companies in drug development and more mature businesses within the medical technology sphere. By targeting investments in both private and public entities, as well as in research-oriented and operational companies, Linc AB delivers comprehensive support to the Nordic region's innovative businesses. With financial commitments ranging from SEK 25 million ($2.99 million) to SEK 250 million ($29.99 million), Linc AB demonstrates flexibility and a tailored approach in fostering the growth of its portfolio companies, often starting with a modest initial investment followed by larger, subsequent financings to support ongoing development and expansion.

Products and Services

Linc AB's portfolio encapsulates a diverse array of products and services, reflecting its broad investment mandate across the pharmaceutical, life-science, and med-tech domains. Here's a closer look:

• Pharmaceutical Investments:

At the heart of Linc AB's investment strategy lies a keen focus on innovative companies engaged in the development of novel pharmaceutical drugs. By investing primarily in early-stage drug development projects, Linc AB aims to propel groundbreaking therapies from conceptualization to commercial realization, addressing unmet medical needs across various therapeutic areas.

• Life-Science Investments:

Linc AB extends its expertise to the life sciences sector, backing companies that are at the forefront of biological research and biotechnology. This encompasses a broad spectrum of applications, from diagnostic tools and bioinformatics to advanced therapies, reflecting the firm's commitment to supporting scientific advancements that have the potential to revolutionize healthcare.

• Med-Tech Investments:

Diverging slightly from its approach in the pharmaceutical and life sciences sectors, Linc AB's med-tech investments focus on more mature businesses. The aim is to foster innovation in medical technology by supporting companies that develop, manufacture, and distribute medical devices and technologies that improve patient outcomes, enhance diagnostic accuracy, and optimize therapeutic interventions. Linc AB's strategic investments in this sector are pivotal in bringing cutting-edge medical solutions to the market.

• Research and Operational Company Investments:

Beyond direct product development, Linc AB also invests in companies that are integral to the operational and research facets of the healthcare industry. This includes entities involved in clinical trials, regulatory affairs, and healthcare services, underscoring Linc AB's holistic approach to fostering innovation and excellence within the healthcare ecosystem.